PTO/SB/30 (5/2000) ed for use through xx/xx/xxxx. OMB 0651-0031 x Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trade Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REQUEST **FOR**

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

Express Mail No.	EL 500 576 635 US	1011
Application Number	09/674,877	. 1
Filing Date	January 2, 2001	Es C
First Named Inventor	Hoefle et al.	1600
Group Art Unit	1625	75
Examiner Name	C. Aulakh	
Attorney Docket Number	6013-192-999 (Previously 2727-127)	

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to

consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1.	S	uhm	ission required under 37 C.F.R. § 1.114		
	. o	Previously submitted			
	i.		Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on(Any unentered amendment(s) referred to above will be entered).		
	ii.		Consider the arguments in the Appeal Brief or Reply Brief previously filed on		
	iii.		Other		
b.	. ⊠	En	Enclosed		
	i.	\boxtimes	Amendment/Reply		
	ii.		Affidavit(s)/Declaration(s)		
	iii.	Ø	Information Disclosure Statement (IDS)		
	iv.	0	Other		
2.	2. Miscellaneous				
a.		Sus of_	spension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)		
b.			ner		
3.	Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed				
a.	Ø	The Director is hereby authorized to charge the following fees, or credit any overpayments, to Pennie & Edmonds LLP Deposit Account No. 16-1150:			
	i.	Ø	RCE fee required under 37 C.F.R. § 1.17(e), estimated to be \$_740.00		
	ii.		Extension of time fee required under 37 C.F.R. §§ 1.136 and 1.17, estimated to be \$ for a month extension, the request for which is being made herewith		
	iii.		·		
b.		Che	eck in the amount of \$ enclosed		
c.			ment by credit card (Form PTO-2038 enclosed)		
			SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED		
Name (Print/Type) Anthony M. Insogna		уре)	Anthony M. Insogna Registration No. (Attorney/Agent) 35,203		
Signatur	е		mthm, W chaon Date October 6, 2002		
	D				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Commissioner for Patents, Box RCE, Washington, DC 20231.

11/12/2002 WABDELR1 00000013 161150 09674877

01 FC:1801

740.00 CH

NOV 0 6. 2002

Express Mail No.: EL 500 57

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hoefle et al.

Confirmation No.: 5629

Application No.: 09/674,877

Group Art Unit: 1625

Filed: January 2, 2001

Examiner: C. Aulakh

For:

EPOTHILONE DERIVATIVES, A

METHOD FOR THE

PRODUCTION THEREOF, AND

THEIR USE

Attorney Docket No.: 6013-192-999

(Previously: 2727-127)

AMENDMENT UNDER 37 C.F.R. § 1.114

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice of Allowability issued August 6, 2002, and in accordance with the Rules of Practice, please enter the following amendment and consider the remarks below in connection with a Request for Continued Examination. Submitted as part of the amendment is Exhibit A, a marked up copy of the amended claim.

IN THE CLAIMS:

Please amend claim 7 to read as follows:

7. (Twice amended) Epothilone derivative as in claims 4, 5, 6 or 18 wherein the substituents of the monocyclic aromatic and/or hetero aromatic are C₁₋₆-alkyl, C₂₋₆-alkenyl, and C₂₋₆-alkinyl groups respectively, and fluoro, chloro, bromo or iodo atoms.

REMARKS

Claims 1-14, 18-20 and 22-24 were allowed in the Notice of Allowability issued August 6, 2002 in connection with the above-identified application and were renumbered as 1-20. Claim 7 has been amended to conform to the Examiner's suggestion at page 4 of the